Saniona (SANION) Corporate presentation summary

Company overview and financials

• Focuses on neurological and psychiatric diseases with a partnership-driven business model.

• Market cap of 1.9 BSEK ($212M) as of April 2026; share price SEK 13.98 ($1.53).

• Strong financials: 581 MSEK ($60M) in cash, 820 MSEK ($85M) in total including milestones and property.

• Revenue in 2025 was $42.2M, with profit before tax of $3.1M.

• Multiple ongoing partnerships and a flexible business model to maximize long-term value.

Strategic partnerships and pipeline

• ACP-711 partnered with Acadia for essential tremor; $28M upfront, up to $582M in milestones and royalties.

• SAN2355 partnered with Jazz Pharmaceuticals for epilepsy; $42.5M upfront, up to $992.5M in milestones and royalties.

• Internal pipeline includes SAN2668 (pediatric epilepsy), SAN2219 (refractory focal epilepsy), and SAN2465 (MDD/TRD), all advancing toward Phase 1.

• Pipeline designed for subtype-selective GABA modulation to improve efficacy and safety over benzodiazepines.

• Phase 1 trials for prioritized assets expected to start between late 2026 and early 2027.

Lead asset SAN2668 (pediatric epilepsy)

• Next-generation oral GABA PAM targeting rare, difficult-to-treat pediatric epilepsies.

• Demonstrates robust seizure control in multiple preclinical models with improved safety and no sedation.

• Superior efficacy to non-selective GABA PAMs and additive effects with standard anti-seizure medications.

• No adverse effects on motor performance or sedation in rodents at relevant doses.

• Phase 1 planned for late 2026, with biomarker-driven dose selection and progression to pediatric studies.